Mutual of America Capital Management LLC lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,233 shares of the medical device company’s stock after selling 902 shares during the period. Mutual of America Capital Management LLC’s holdings in DexCom were worth $2,065,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Edmond DE Rothschild Holding S.A. bought a new position in DexCom in the 1st quarter worth approximately $164,000. Brighton Jones LLC acquired a new position in DexCom during the 1st quarter worth $204,000. IFP Advisors Inc boosted its position in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after buying an additional 568 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its position in DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after buying an additional 250 shares during the last quarter.

WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/mutual-of-america-capital-management-llc-lowers-position-in-dexcom-inc-dxcm/1607027.html.

Several equities research analysts have recently commented on the company. Oppenheimer Holdings, Inc. set a $92.00 target price on DexCom and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Cowen and Company restated a “buy” rating and set a $90.00 target price on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets reaffirmed a “buy” rating and set a $105.00 price target on shares of DexCom in a research note on Thursday, July 13th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $78.00 price target on shares of DexCom in a research note on Wednesday, July 12th. Finally, BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $72.19.

In related news, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total transaction of $123,050.10. Following the sale, the executive vice president now owns 72,395 shares in the company, valued at approximately $5,448,447.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew K. Balo sold 3,200 shares of the company’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $71.55, for a total value of $228,960.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,223 shares of company stock worth $2,285,138. 1.70% of the stock is owned by company insiders.

DexCom, Inc. (NASDAQ DXCM) opened at 47.18 on Wednesday. The firm’s 50-day moving average price is $69.77 and its 200 day moving average price is $72.60. The company’s market capitalization is $4.08 billion. DexCom, Inc. has a 12-month low of $42.62 and a 12-month high of $88.80.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. During the same quarter last year, the firm earned ($0.24) earnings per share. DexCom’s quarterly revenue was up 24.3% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post ($0.80) earnings per share for the current year.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.